CRISPR Therapeutics AG

General Information

We are a leading gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR) Associated protein-9 and is a revolutionary technology for gene editing, the process of precisely altering specific sequences of genomic DNA. We are applying this technology to treat a broad set of rare and common diseases by disrupting, correcting or regulating disease-related genes.

Employees: 77
Founded: 2013
Contact Information
Address 111 Eighth Avenue, New York, NY 10011, US
Phone Number (212) 894-8800
Web Address
View Prospectus: CRISPR Therapeutics AG
Financial Information
Market Cap $636.0mil
Revenues $1.3 mil (last 12 months)
Net Income $-44.2 mil (last 12 months)
IPO Profile
Symbol CRSP
Exchange NASDAQ
Shares (millions): 4.0
Price range $14.00 - $14.00
Est. $ Volume $56.0 mil
Manager / Joint Managers Citigroup/ Piper Jaffray/ Barclays
CO-Managers Guggenheim Securities
Expected To Trade: 10/19/2016
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change